Moreover, the 5-year results from the phase III NCT02220894 study highlighted the sustained efficacy of pembrolizumab as a first-line treatment for locally advanced or metastatic NSCLC without EGFR or ALK alterations in all PD-L1 tumor proportion score (TPS) groups compared to chemotherapy [227]. The gene discussed is ALK; the disease is neoplasm.